LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 157

Search options

  1. Article: Emerging trends in clinical cancer genomic research.

    Yu, Yingyan

    Cancer biology & medicine

    2024  Volume 20, Issue 11

    MeSH term(s) Humans ; Neoplasms/genetics ; Neoplasms/therapy ; Genomics
    Language English
    Publishing date 2024-01-03
    Publishing country China
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2676322-9
    ISSN 2095-3941
    ISSN 2095-3941
    DOI 10.20892/j.issn.2095-3941.2023.0383
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Multi-target combinatory strategy to overcome tumor immune escape.

    Yu, Yingyan

    Frontiers of medicine

    2022  Volume 16, Issue 2, Page(s) 208–215

    Abstract: Immune therapy has become the fourth approach after surgery, chemotherapy, and radiotherapy in cancer treatment. Many immune checkpoints were identified in the last decade since ipilimumab, which is the first immune checkpoint inhibitor to cytotoxic T- ... ...

    Abstract Immune therapy has become the fourth approach after surgery, chemotherapy, and radiotherapy in cancer treatment. Many immune checkpoints were identified in the last decade since ipilimumab, which is the first immune checkpoint inhibitor to cytotoxic T-lymphocyte associated protein 4, had been approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma in 2011. The use of several antibody drugs that target PD1/PD-L1 for various cancer treatments has been approved by the FDA. However, fewer people are benefitting from immune checkpoint inhibitor treatment in solid cancers. Approximately 80% of patients do not respond appropriately because of primary or acquired therapeutic resistance. Along with the characterization of more immune checkpoints, the combinatory treatment of multiimmune checkpoint inhibitors becomes a new option when monotherapy could not receive a good response. In this work, the author focuses on the combination therapy of multiple immune checkpoints (does not include targeted therapy of oncogenes or chemotherapy), introduces the current progression of multiple immune checkpoints and their related inhibitors, and discusses the advantages of combination therapy, as well as the risk of immune-related adverse events.
    MeSH term(s) Combined Modality Therapy ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Melanoma/drug therapy ; Tumor Escape
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-04-04
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2617113-2
    ISSN 2095-0225 ; 2095-0217
    ISSN (online) 2095-0225
    ISSN 2095-0217
    DOI 10.1007/s11684-022-0922-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers.

    Yu, Yingyan

    Cancer biology & medicine

    2021  

    Language English
    Publishing date 2021-10-22
    Publishing country China
    Document type Editorial
    ZDB-ID 2676322-9
    ISSN 2095-3941
    ISSN 2095-3941
    DOI 10.20892/j.issn.2095-3941.2021.0491
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Patient-derived organoids in translational oncology and drug screening.

    Yang, Ruixin / Yu, Yingyan

    Cancer letters

    2023  Volume 562, Page(s) 216180

    Abstract: Patient-derived organoids (PDO) are a new biomedical research model that can reconstruct phenotypic and genetic characteristics of the original tissue and are useful for research on pathogenesis and drug screening. To introduce the progression in this ... ...

    Abstract Patient-derived organoids (PDO) are a new biomedical research model that can reconstruct phenotypic and genetic characteristics of the original tissue and are useful for research on pathogenesis and drug screening. To introduce the progression in this field, we review the key factors of constructing organoids derived from epithelial tissues and cancers, covering culture medium and matrix, morphological characteristics, genetic profiles, high-throughput drug screening, and application potential. We also discuss the co-culture system of cancer organoids with tumor microenvironment (TME) associated cells. The co-culture system is widely used in evaluating crosstalk of cancer cells with TME components, such as fibroblasts, endothelial cells, immune cells, and microorganisms. The article provides a prospective for standardized cultivation mode, automatic morphological evaluation, and drug sensitivity screening using high-throughput methods.
    MeSH term(s) Humans ; Drug Evaluation, Preclinical ; Endothelial Cells ; Prospective Studies ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Organoids/pathology ; Tumor Microenvironment
    Language English
    Publishing date 2023-04-13
    Publishing country Ireland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2023.216180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1177: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.

    Yu, Yingyan / Peng, Wenjie

    Cancer biology & medicine

    2023  Volume 20, Issue 5

    Abstract: Malignant tumors are complex structures composed of cancer cells and tumor microenvironmental cells. In this complex structure, cells cross-talk and interact, thus jointly promoting cancer development and metastasis. Recently, immunoregulatory molecule- ... ...

    Abstract Malignant tumors are complex structures composed of cancer cells and tumor microenvironmental cells. In this complex structure, cells cross-talk and interact, thus jointly promoting cancer development and metastasis. Recently, immunoregulatory molecule-based cancer immunotherapy has greatly improved treatment efficacy for solid cancers, thus enabling some patients to achieve persistent responses or cure. However, owing to the development of drug-resistance and the low response rate, immunotherapy against the available targets PD-1/PD-L1 or CTLA-4 has limited benefits. Although combination therapies have been proposed to enhance the response rate, severe adverse effects are observed. Thus, alternative immune checkpoints must be identified. The SIGLECs are a family of immunoregulatory receptors (known as glyco-immune checkpoints) discovered in recent years. This review systematically describes the molecular characteristics of the SIGLECs, and discusses recent progress in areas including synthetic ligands, monoclonal antibody inhibitors, and Chimeric antigen receptor T (CAR-T) cells, with a focus on available strategies for blocking the sialylated glycan-SIGLEC axis. Targeting glyco-immune checkpoints can expand the scope of immune checkpoints and provide multiple options for new drug development.
    MeSH term(s) Humans ; Sialic Acid Binding Immunoglobulin-like Lectins ; Immunotherapy ; Neoplasms/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Polysaccharides
    Chemical Substances Sialic Acid Binding Immunoglobulin-like Lectins ; Antibodies, Monoclonal ; Polysaccharides
    Language English
    Publishing date 2023-05-08
    Publishing country China
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2676322-9
    ISSN 2095-3941
    ISSN 2095-3941
    DOI 10.20892/j.issn.2095-3941.2023.0046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Human pangenome: far-reaching implications in precision medicine.

    Yu, Yingyan / Chen, Hongzhuan

    Frontiers of medicine

    2023  

    Language English
    Publishing date 2023-12-29
    Publishing country China
    Document type Journal Article
    ZDB-ID 2617113-2
    ISSN 2095-0225 ; 2095-0217
    ISSN (online) 2095-0225
    ISSN 2095-0217
    DOI 10.1007/s11684-023-1039-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.

    Yu, Yingyan

    Frontiers of medicine

    2017  Volume 12, Issue 2, Page(s) 229–235

    Abstract: On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor ... ...

    Abstract On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as "genetic interpreters" or "genetic translators" and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
    MeSH term(s) Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Humans ; Neoplasms/drug therapy ; Precision Medicine ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome ; United States
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; Programmed Cell Death 1 Receptor ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2017-12-05
    Publishing country China
    Document type Journal Article
    ZDB-ID 2617113-2
    ISSN 2095-0225 ; 2095-0217
    ISSN (online) 2095-0225
    ISSN 2095-0217
    DOI 10.1007/s11684-017-0581-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: IncRNA MIAT Accelerates Keloid Formation by miR-411-5p/JAG1 Axis.

    Yu, Yingyan / Dong, Yujie / Deng, Benyuan / Yang, Ting

    Critical reviews in eukaryotic gene expression

    2023  Volume 33, Issue 2, Page(s) 81–92

    Abstract: The long non-coding RNA (lncRNA) myocardial infarction-associated transcript (MIAT) regulates the biological functions of many kinds of cells. The aim of this study is to explore the mechanism of MIAT and how it affects keloid progression. The ... ...

    Abstract The long non-coding RNA (lncRNA) myocardial infarction-associated transcript (MIAT) regulates the biological functions of many kinds of cells. The aim of this study is to explore the mechanism of MIAT and how it affects keloid progression. The expressions of MIAT, JAG1, and miR-411-5p in keloid tissues and keloid fibroblasts (KEL FIBs) were quantified by conducting Western blot and quantitative reverse transcription polymerase chain reaction analyses. The influences of MIAT, JAG1, and miR-411-5p on the abilities of KEL FIBs to proliferate, migrate, and invade were assessed by means of the CCK-8, wound healing, and Transwell experiments. To determine the binding relationship among MIAT, JAG1, and miR-411-5p, we performed luciferase reporter and RIP experiments. In keloid tissues and KEL FIBs, MIAT and JAG1 were upregulated while miR-411-5p was downregulated. Knocking-down MIAT or JAG1 significantly inhibited proliferation, migration and invasion. On the contrary, suppressing miR-411-5p expression produced an opposite effect. With regard to mechanisms, MIAT sponged miR-411-5p, which targeted JAG1. MIAT accelerates keloid formation by modulating the miR-411-5p/JAG1 axis.
    MeSH term(s) Humans ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Keloid/genetics ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Myocardial Infarction ; Cell Proliferation/genetics ; Jagged-1 Protein/genetics ; Jagged-1 Protein/metabolism
    Chemical Substances MicroRNAs ; RNA, Long Noncoding ; JAG1 protein, human ; Jagged-1 Protein ; MIRN411 microRNA, human
    Language English
    Publishing date 2023-02-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1071345-1
    ISSN 1045-4403
    ISSN 1045-4403
    DOI 10.1615/CritRevEukaryotGeneExpr.2022044734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3226: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers.

    Yang, Ruixin / Yu, Yingyan

    International journal of biological sciences

    2021  Volume 17, Issue 6, Page(s) 1530–1537

    Abstract: Glucocorticoids are important steroid hormones. As an outstanding scientific discovery, the scientist who discovered glucocorticoids was awarded the Nobel Prize in Physiology and Medicine in 1950. Cortisone (hydrocortisone) is a natural glucocorticoid, ... ...

    Abstract Glucocorticoids are important steroid hormones. As an outstanding scientific discovery, the scientist who discovered glucocorticoids was awarded the Nobel Prize in Physiology and Medicine in 1950. Cortisone (hydrocortisone) is a natural glucocorticoid, which is secreted with circadian rhythm by the cortical cells of adrenal glands. Physiologically, about 10-20 mg of hydrocortisone are secreted each day for maintaining homeostasis. Since the biological half-life of natural glucocorticoid is short, scientists developed various synthetic glucocorticoids including prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, and so on. These synthetic glucocorticoids are generated by modifying some structures based on the cortisone backbone, leading to extension of their biological half-life with stronger activities. In the face of severe infection, allergy, shock, trauma, pain, and other stresses, the demand for glucocorticoids increases dramatically. It is critical to supplement extra glucocorticoids to protect the biological functions of vital organs. However, the amount and duration of glucocorticoid administration need to be carefully adjusted, because a series of side effects may occur after long-term or high-dose usage of glucocorticoids. This review article will discuss the application of glucocorticoids in the treatment of patients with severe or critical COVID-19 and solid tumors of advanced stage. The controversy of using glucocorticoid in medical community will also be discussed. This review article will help doctors and basic researchers better understand the practical application of glucocorticoids.
    MeSH term(s) COVID-19/virology ; Glucocorticoids/therapeutic use ; Humans ; Neoplasms/drug therapy ; SARS-CoV-2/isolation & purification ; COVID-19 Drug Treatment
    Chemical Substances Glucocorticoids
    Language English
    Publishing date 2021-04-10
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2179208-2
    ISSN 1449-2288 ; 1449-2288
    ISSN (online) 1449-2288
    ISSN 1449-2288
    DOI 10.7150/ijbs.58695
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Artificial Convolutional Neural Network in Object Detection and Semantic Segmentation for Medical Imaging Analysis.

    Yang, Ruixin / Yu, Yingyan

    Frontiers in oncology

    2021  Volume 11, Page(s) 638182

    Abstract: In the era of digital medicine, a vast number of medical images are produced every day. There is a great demand for intelligent equipment for adjuvant diagnosis to assist medical doctors with different disciplines. With the development of artificial ... ...

    Abstract In the era of digital medicine, a vast number of medical images are produced every day. There is a great demand for intelligent equipment for adjuvant diagnosis to assist medical doctors with different disciplines. With the development of artificial intelligence, the algorithms of convolutional neural network (CNN) progressed rapidly. CNN and its extension algorithms play important roles on medical imaging classification, object detection, and semantic segmentation. While medical imaging classification has been widely reported, the object detection and semantic segmentation of imaging are rarely described. In this review article, we introduce the progression of object detection and semantic segmentation in medical imaging study. We also discuss how to accurately define the location and boundary of diseases.
    Language English
    Publishing date 2021-03-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.638182
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top